Health Care Sector Update for 06/12/2019: TEVA,IMRN,SYBX,CTRV

Shutterstock photo

Top Health Care Stocks

JNJ +1.36%

PFE +0.61%

ABT +0.52%

MRK +1.24%

AMGN +0.53%

Health care stocks were outpacing most other sectors shortly before Wednesday's closing bell. At last look, the NYSE Health Care Index was climbing about 0.5% while shares of health care companies in the S&P 500 also were up over 0.2% as a group. The Nasdaq Biotechnology index also was ahead almost 0.5% this afternoon.

Among health care stocks moving on news:

(-) Teva Pharmaceutical Industries ( TEVA ) slumped Wednesday, falling almost 4%, following reports the drugmaker's $85 million settlement with the state of Oklahoma for its role in the country's opioid crisis has stalled. An Oklahoma judge sent the proposed settlement back to attorneys from both sides for more work to make sure it complies with a new state law, according to the Associated Press

In other sector news:

(+) Synlogic ( SYBX ) was 25% higher after the synthetic biotic drug-maker said it was using Ginkgo's cell programming platform to build and test thousands of microbial strains and accelerate the development of potential drug candidates. Ginkgo also invested $80 million in Synlogic, buying over 6.34 million of its common shares and nearly 2.55 million pre-funded warrants, both at $9 apiece, while Synlogic paid $30 million to Ginkgo for synthetic biology services over the next five years.

(+) Immuron ( IMRN ) rallied Wednesday, climbing nearly 14% after the biotech company said its Travelan drug candidate prevented bacillary dysentery in 75% of the non-human primates treated in a preclinical study of the anti-biotic alternative. The trial used eight juvenile rhesus monkeys in the Travelan cohort that were treated twice daily for a total of 12 doses in addition to four monkeys in the placebo group.

(-) ContraVir Pharmaceuticals ( CTRV ) tumbled over 15% after disclosing plans to sell nearly 2.9 million Class A units consisting of one share of common stock and a warrant to buy another share. Certain institutional investors participating in the stock sale are eligible to instead buy Class B units containing ContraVir's Series E preferred stock convertible into common stock as well as warrants to purchase more shares.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing , US Markets
Referenced Symbols: TEVA , SYBX , IMRN , CTRV

More from MT Newswires


MT Newswires

MT Newswires

Market News, Commodities

Research Brokers before you trade

Want to trade FX?